FDA Inspection
WES Pharma Inc.WES Pharma Inc. – FDA Inspection, Nov 21, 2023
Record Details
This FDA Inspection record concerns WES Pharma Inc., with an inspection on November 21, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 37ef8a8b-4e2f-433a-b55a-1a0aa0bf154b
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1223324
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
4- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.63Equipment Design, Size and Location
Full citation text and observation details available on the Dashboard.
Other FDA inspections of WES Pharma Inc.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| November 20, 2025 | VAI | Baltimore District Office | Drug Quality Assurance |
| February 18, 2022 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 28, 2021 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| December 20, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 19, 2019 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for WES Pharma Inc.
- FDA Inspection 1290200 - 2025-11-20
- FDA Inspection 1162565 - 2022-02-18
- FDA Inspection 1141774 - 2021-04-28
- FDA Inspection 1114327 - 2019-12-20
- FDA Inspection 1088267 - 2019-04-19
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.